TY - CHAP
T1 - New Targeted Therapies for Bone Metastases
AU - Lipton, Allan
AU - Costa, Luis
AU - Sieber, Paul
AU - Dougall, William C.
AU - Braun, Ada
PY - 2014
Y1 - 2014
N2 - A number of targeted agents under investigation or in development have shown promise in the treatment or prevention of bone metastases. Among them is denosumab (XGEVA, Amgen Inc.), a fully human monoclonal antibody targeting the RANK ligand (RANKL) pathway that was approved on 18 November 2010 in the United States (Amgen XGEVA [denosumab] prescribing information, 2012). Denosumab has been proven superior to zoledronic acid in preserving skeletal function and integrity by preventing skeletal complications among patients with bone metastases from solid tumors. Denosumab has demonstrated prolongation of bone metastasis-free survival in men with castration-resistant prostate cancer and is being investigated for this outcome in women with early-stage breast cancer. Another study is prospectively evaluating a potential prolongation of overall survival with denosumab in patients with metastatic lung cancer. Also currently in development are numerous targeted agents that impact the function of the various growth factors released from the bone matrix that stimulate tumor growth, bone destruction, and lead to bone metastases.
AB - A number of targeted agents under investigation or in development have shown promise in the treatment or prevention of bone metastases. Among them is denosumab (XGEVA, Amgen Inc.), a fully human monoclonal antibody targeting the RANK ligand (RANKL) pathway that was approved on 18 November 2010 in the United States (Amgen XGEVA [denosumab] prescribing information, 2012). Denosumab has been proven superior to zoledronic acid in preserving skeletal function and integrity by preventing skeletal complications among patients with bone metastases from solid tumors. Denosumab has demonstrated prolongation of bone metastasis-free survival in men with castration-resistant prostate cancer and is being investigated for this outcome in women with early-stage breast cancer. Another study is prospectively evaluating a potential prolongation of overall survival with denosumab in patients with metastatic lung cancer. Also currently in development are numerous targeted agents that impact the function of the various growth factors released from the bone matrix that stimulate tumor growth, bone destruction, and lead to bone metastases.
UR - http://www.scopus.com/inward/record.url?scp=84896818189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896818189&partnerID=8YFLogxK
U2 - 10.1007/978-94-007-7569-5_12
DO - 10.1007/978-94-007-7569-5_12
M3 - Chapter
AN - SCOPUS:84896818189
SN - 9789400775688
T3 - Cancer Metastasis - Biology and Treatment
SP - 235
EP - 246
BT - Bone Metastases
A2 - Vassiliou, Vassilios
A2 - Chow, Edward
A2 - Kardamakis, Dimitrios
ER -